An earlier disruption to our telephone service has been rectified. Please note you may still experience some delays. We apologise for any inconvenience caused and appreciate your patience.

15th May 2024

Mater Private Network selected as one of three centres worldwide for Global AFib Study

Location: Dublin

Mater Private Network has been selected as one of only three centres worldwide and the only centre in Ireland to participate in the prestigious NAVIGATE-PF clinical study, led by Boston Scientific. This recognition highlights Mater Private Network's status as one of the most acknowledged atrial fibrillation (AFib) centres in Europe.

The prospective, single-arm, open-label, multi-centre NAVIGATE-PF study will begin at the Dublin site from today, Friday 10th May, marking a significant step in Mater Private Network's involvement in pioneering medical research. AFib is the most common irregular heart rhythm, which significantly reduces the quality of life and life expectancy of patients. An estimated 8 million patients live with this condition in Europe.

The NAVIGATE-PF study will examine the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration with the Boston Scientific cardiac mapping system. The FARAWAVE Nav PFA Catheter adds magnetic navigation capabilities to the current FARAWAVE PFA catheter, enabling detailed mapping and PFA therapy within the same device. 

This mapping data is visualiszed using the new FARAVIEW Software Module, offering a tailored mapping solution for procedures with the FARAPULSE PFA System. This will be the second generation of the novel FARAWAVE catheter as a part of the FARAPULSE PFA System, which has had extensive real-world use demonstrating safety of the system with no reports of permanent phrenic nerve palsy, pulmonary vein stenosis or oesophageal injury.

Prof. Gábor Széplaki, Head of Cardiac Electrophysiology at Mater Private Network, expressed his enthusiasm for the project: "We are honoured to participate in this groundbreaking study, which will be another milestone in our journey to transform the way arrhythmias are treated globally. This initiative represents a significant stride towards integrating advanced cardiac mapping with ablation technology, aiming to elevate the standard of care for our patients with atrial fibrillation. As a centre of excellence in cardiac electrophysiology, we are committed to contributing to research that may significantly improve patient outcomes. As early adaptors of the most advanced technologies we are hoping to deliver safe and efficient therapies to the wider patient populations, including elderly patients living with atrial fibrillation."

Mater Private Network continues to demonstrate its commitment to medical innovation and dedication to providing the latest and most effective treatments to its patients. The Electrophysiology team is offering comprehensive, multi-disciplinary patient management at the Atrial Fibrillation Institute in Dublin. The network remains focused on advancing medical science and improving the health of those it serves.

In a pulsed field cardiac ablation procedure, a catheter is guided into the heart to administer targeted non-thermal electrical fields that selectively treat heart tissue cells, while avoiding damage to nearby structures. Mater Private Network has been one of the first centres which has adopted the groundbreaking technology and delivered >750 procedures since 2022.